Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma

Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem-like Cell Resistance to EGFR-Targeted Inhibition

(2015) Paul A. Clark et al.   NEOPLASIA

The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III

(2015) Yaqiong Yang et al.   NEOPLASIA

The Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma Multiforme and other Malignant Neoplasms

(2012) S. Loew et al.   Anti-Cancer Agents in Medicinal Chemistry

STAT3 as a Therapeutic Target for Glioblastoma

(2012) Yan Liu et al.   Anti-Cancer Agents in Medicinal Chemistry

RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls

(2012) Mikkel Noerholm et al.   BMC CANCER

Blockade of EGFR signaling promotes glioma stem-like cell invasiveness by abolishing ID3-mediated inhibition of p27KIP1 and MMP3 expression

(2012) Xun Jin et al.   CANCER LETTERS

The MET Oncogene Is a Functional Marker of a Glioblastoma Stem Cell Subtype

(2012) F. De Bacco et al.   CANCER RESEARCH

Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis

(2012) Wei Meng et al.   CELL BIOLOGY INTERNATIONAL

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence

(2012) Sai-Hong Ignatius Ou   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance

(2012) T. E. Taylor et al.   CURRENT CANCER DRUG TARGETS

Epidermal growth factor receptor

(2012) Monika E. Hegi et al.   CURRENT OPINION IN NEUROLOGY

Emerging insights into the molecular and cellular basis of glioblastoma

(2012) G. P. Dunn et al.   GENES & DEVELOPMENT

Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway

(2012) Ke Sai et al.   JOURNAL OF NEURO-ONCOLOGY

Molecular Characterization of EGFR and EGFRvIII Signaling Networks in Human Glioblastoma Tumor Xenografts

(2012) Hannah Johnson et al.   MOLECULAR & CELLULAR PROTEOMICS

Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

(2012) Huilin Shao et al.   NATURE MEDICINE

Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

(2012) Shota Tanaka et al.   Nature Reviews Clinical Oncology

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells

(2012) Owen D. Stechishin et al.   NEURO-ONCOLOGY

Gene therapy for brain tumors: Basic developments and clinical implementation

(2012) Hikmat Assi et al.   NEUROSCIENCE LETTERS

Superselective Intra-Arterial Cerebral Infusion of Novel Agents After Blood–Brain Disruption for the Treatment of Recurrent Glioblastoma Multiforme: A Technical Case Series

(2012) Benjamin J. Shin et al.   NEUROSURGERY CLINICS OF NORTH AMERICA

EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms

(2012) C A Del Vecchio et al.   ONCOGENE

A Simplified Approach for the Molecular Classification of Glioblastomas

(2012) Marie Le Mercier et al.   PLoS One

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240

(2012) T. R. Fenton et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis

(2012) H. Feng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de não pequenas células

(2012) A.S. Castro et al.   Revista Portuguesa de Pneumologia

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

(2012) Igor Vivanco et al.   Cancer Discovery

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

(2011) Toni M. Brand et al.   CANCER BIOLOGY & THERAPY

Nonreceptor Tyrosine Kinase BMX Maintains Self-Renewal and Tumorigenic Potential of Glioblastoma Stem Cells by Activating STAT3

(2011) Olga A. Guryanova et al.   CANCER CELL

TGF-β2 Signaling in High-Grade Gliomas

(2011) Peter Hau et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Targeting ErbB Receptors in High-Grade Glioma

(2011) Sabina Berezowska et al.   CURRENT PHARMACEUTICAL DESIGN

Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme

(2011) Marie-Thérése Stockhausen et al.   EXPERIMENTAL CELL RESEARCH

Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain

(2011) Sagar Agarwal et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Cooperative Hedgehog-EGFR signaling

(2011) Doris Mangelberger   Frontiers in Bioscience-Landmark

Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models

(2011) Sharon L. Longo et al.   INVESTIGATIONAL NEW DRUGS

Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma

(2011) Ming Li et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma

(2011) Ning Bu et al.   JOURNAL OF NEURO-ONCOLOGY

Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells

(2011) Kamila A. Adamczyk et al.   LIFE SCIENCES

Synergistic Induction of Apoptosis in Brain Cancer Cells by Targeted Codelivery of siRNA and Anticancer Drugs

(2011) Cheoljin Kim et al.   MOLECULAR PHARMACEUTICS

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

A multigene predictor of outcome in glioblastoma

(2011) H. Colman et al.   NEURO-ONCOLOGY

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

(2011) R Bonavia et al.   ONCOGENE

Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments

(2011) Douglas D. Taylor et al.   Seminars in Immunopathology

Oncogenic EGFR Signaling Activates an mTORC2-NF- B Pathway That Promotes Chemotherapy Resistance

(2011) K. Tanaka et al.   Cancer Discovery

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

A novel hybrid peptide targeting EGFR-expressing cancers

(2010) Masayuki Kohno et al.   EUROPEAN JOURNAL OF CANCER

RNA interference therapy for glioblastoma

(2010) Dongsheng Guo et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence

(2010) Anna Elisa Quatrale   Frontiers in Bioscience-Landmark

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

(2010) M.-d.-M. Inda et al.   GENES & DEVELOPMENT

The Constitutive Activity of Epidermal Growth Factor Receptor vIII Leads to Activation and Differential Trafficking of Wild-type Epidermal Growth Factor Receptor and erbB2

(2010) Reema Zeineldin et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

A Phase II study of anti–epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme

(2010) Linna Li et al.   JOURNAL OF NEUROSURGERY

Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status

(2010) Xuan Zhou et al.   LABORATORY INVESTIGATION

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

(2010) W. K. A. Yung et al.   NEURO-ONCOLOGY

Cetuximab, its clinical use and future perspectives

(2009) Fernando Rivera et al.   ANTI-CANCER DRUGS

A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation

(2009) Brian Thiessen et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Nuclear Translocation of the Epidermal Growth Factor Receptor Family Membrane Tyrosine Kinase Receptors

(2009) S.-C. Wang et al.   CLINICAL CANCER RESEARCH

Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-κB and initiates tumour vascular normalization

(2009) Hui K. Gan et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Antitumor activity of a novel antisense oligonucleotide against Akt1

(2009) Heejeong Yoon et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme

(2009) David M. Peereboom et al.   JOURNAL OF NEURO-ONCOLOGY

Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib

(2009) Marc-Eric Halatsch et al.   JOURNAL OF NEUROSURGERY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?

(2009) G. Karpel-Massler et al.   MOLECULAR CANCER RESEARCH

An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme

(2009) J. H. Sampson et al.   MOLECULAR CANCER THERAPEUTICS

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Development of HKI‐272 and Related Compounds for the Treatment of Cancer

(2008) Allan Wissner et al.   ARCHIV DER PHARMAZIE

Proteomic and immunologic analyses of brain tumor exosomes

(2008) Michael W. Graner et al.   FASEB JOURNAL

Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

(2008) Rafael G. Amado et al.   JOURNAL OF CLINICAL ONCOLOGY

Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles

(2008) Thomas Schneider et al.   JOURNAL OF NEUROIMMUNOLOGY

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

(2008) Roger McLendon et al.   NATURE

Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

(2008) Johan Skog et al.   NATURE CELL BIOLOGY

Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma

(2008) A. Idbaih et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipomatous supratentorial primitive neuroectodermal tumor with glioblastomatous differentiation

(2007) Richard A. Prayson   Annals of Diagnostic Pathology